722P Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial
| Autor: | Gladieff, L., Martinez-Garcia, J., Takekuma, M., Villacampa, G., De Giorgi, U., Harter, P., Hellman, K., Duska, L., Ortiz, A. Godoy, Bellier, C., Nishio, H., Pérez, M.J. Rubio, Delanoy, N., Madrid, L. Fariñas, Berton, D., Alarcon, J.D., Kurtz, J.E., Nishino, K., Randall, L.M., Oaknin, A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S552-S552 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|